IN8bio, Inc. (INAB)

Compare

0.1727

+0.0067

+(4.04%)

At close: April 1 at 4:00:01 PM EDT

0.1799

+0.01

+(4.17%)

After hours: April 1 at 7:54:48 PM EDT

IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025

NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced today a poster presentation on its potentially breakthrough next generation γδ T cell-based T cell engager (TCE) platform at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025 in Chicago, IL. “T cell engagers are an exciting area of

GlobeNewswire yesterday

INAB
+4.04%
IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that the Company will participate in multiple sessions at the Immuno-Oncology 360° (IO360°) Conference 2025, held March 24-26, 2025, in Boston, MA. William Ho, Chief Executive Officer and co-founder of IN8bio, will be Co-Chairing Day 2 of the conference starting at 8:15 AM EDT on

GlobeNewswire 14 days ago

INAB
+4.04%
INAB: Introducing INB-600, A γδ T Cell Engager Platform

By John Vandermosten, CFA NASDAQ:INAB READ THE FULL INAB RESEARCH REPORT Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc. (NASDAQ:INAB) reported 2024 financial and operational results on March 14 th , 2025. Other corporate achievements since the third quarter report in mid-November include a stakeholder update on glioblastoma multiforme (GBM) and acute

Zacks Small Cap Research 15 days ago

INAB
+4.04%
IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, including glioblastoma (GBM) and 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-freeExpanded pipeline with INB-600 platform, featuring novel gamma-delta T Cell engager (TCE) targeting CD19 for potential use in oncology and autoimmune diseasesContinued operational execution with strengthened strategic focus on aligning resources in an effort to drive hi

GlobeNewswire 19 days ago

INAB
+4.04%
IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases

Proprietary platform represents the first known approach capable of sustained γδ T cell expansion, eliminating target cells with robust potencyINB-619, a next generation γδ TCE targeting CD19, eradicates B cells in preclinical models, maintaining depletion over time as γδ T cells expand in response to TCE stimulation γδ TCE targets and expands both Vδ1+ and Vδ2+ T cells, potentially leading to longer lasting immune responses and deeper B cell depletionUnlike traditional TCEs and CAR-T therapies,

GlobeNewswire 29 days ago

INAB
+4.04%
IN8bio to Present at the TD Cowen 45th Annual Health Care Conference

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will be presenting at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET. A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at https://investors.i

GlobeNewswire last month

INAB
+4.04%
IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will be presenting at the: H.C. Wainwright 3rd Annual Cell Therapy Virtual ConferenceDate/Time Tuesday, February 25, 2025, at 11:00 a.m. ET. Webcast Link https://journey.ct.events/view/acb6057e-9d9b-427e-b490-eaf85a5c2910 A live webcast and replay will be available under

GlobeNewswire last month

INAB
+4.04%
INAB: Continued Survival in INB-100 Trial

By John Vandermosten, CFA NASDAQ:INAB READ THE FULL INAB RESEARCH REPORT IN8bio, Inc (NASDAQ:INAB) updates survival data for its INB-100 trial in a February 11 th press release in preparation for presentation of data at the Transplantation & Cellular Therapy (TCT) Meetings in Hawaii last week. Data for patients enrolled in the trial were updated from early August 2024 to January 17 th ,

Zacks Small Cap Research last month

INAB
+4.04%
IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML

NEW YORK, Feb. 14, 2025 (GLOBE NEWSWIRE) -- February 14, 2025 – IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, yesterday presented Phase 1 data on its allogeneic gamma-delta T cell therapy, INB-100, at the 2025 Transplantation & Cellular Therapy (TCT) Meetings in Hawaii. The data, previously announced, reinforce INB-100’s potential to significantly reduce post-transplant relapse in high-risk acute myeloid leukemia (AML)

GlobeNewswire last month

INAB
+4.04%
IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

100% of acute myeloid leukemia (AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 months AML patients treated demonstrated one-year progression-free survival (PFS) and overall survival (OS), exceeding real-world control groups Patients treated with INB-100 demonstrating prolonged and durable remissions supported by gamma-delta T cell persistence beyond one year Company to host conference call at 8:30am EST today. Use this

GlobeNewswire last month

INAB
+4.04%
IN8bio to Present at Biotech Showcase 2025 in San Francisco

NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will participate at Biotech Showcase 2025 on a panel on Monday, January 13, 2025, and present on Tuesday, January 14, 2025, at the Hilton San Francisco Union Square Hotel in San Francisco, CA. Details for the event are provided below. Biotech Showcase, January 13 - 15, 2025 Panel: Th

GlobeNewswire 2 months ago

INAB
+4.04%
IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

INB-100 continues to demonstrate durable complete remissions (CR) with no relapses observed in any acute myeloid leukemia (AML) patients including those with high-risk disease after a median follow-up of 19.7 months. Data highlights INB-100’s long-term impact, exhibiting durable in vivo expansion and persistence of allogeneic gamma-delta T cells 365 days following a single administration of INB-100, demonstrating the first-ever durable persistence and expansion of an allogeneic cellular therapy.

GlobeNewswire 3 months ago

INAB
+4.04%
IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference

NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will present at NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference on Tuesday, December 3, 2024 at 10:30 am ET. A high-definition video webcast of the presentation will be available the following day on the Company's website https://investors.i

GlobeNewswire 3 months ago

INAB
+4.04%
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting

50% of patients who received repeated doses (n=10) remained alive and in remission beyond the expected median overall survival (OS) from standard-of-care Stupp regimen while none of the patients who received a single dose (n=3) achieved this outcome. Biopsy results confirmed the presence and persistence of gamma-delta T cells along with CD3+ and CD8+ T cells within the brain tumor microenvironment in two patients following treatment with INB-200. Patients in the multi-dose cohorts demonstrated a

GlobeNewswire 4 months ago

INAB
+4.04%
INAB: Upcoming Presentations at SNO & ASH

By John Vandermosten, CFA NASDAQ:INAB READ THE FULL INAB RESEARCH REPORT IN8bio, Inc (NASDAQ:INAB) reported third quarter 2024 financial results and achievements on November 12 th . Activity since the second quarter update was dominated by a restructuring and narrowing of focus towards the INB-100 program and the raise of $12.4 million in a private placement. The company also announced its

Zacks Small Cap Research 4 months ago

INAB
+4.04%
IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology Association Congress and received FDA guidance for a future INB-100 registrational trialINB-100 trial currently expanding enrollment up to approximately 25 patients at the recommended Phase 2 dose (RP2D) along with the potential to add additional centers and a prospective parallel observational cohort as a controlClosed private placement for net proceeds of

GlobeNewswire 4 months ago

INAB
+4.04%
IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting

Plenary Oral Presentation at SNO will provide latest clinical trial results from the previously enrolled INB-200 studies of autologous gamma-delta T cells for newly diagnosed glioblastoma (GBM) NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming plenary oral presentation at the 29th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO)

GlobeNewswire 4 months ago

INAB
+4.04%
IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting

NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming poster presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, being hosted December 7 – 10, 2024 in San Diego, CA. Details for the ASH 2024 presentation are as follows: Title: INB-100: Pilot Study of Donor Derived, ex-vivo Expanded/Activated Gamma-Delta T cell Infus

GlobeNewswire 4 months ago

INAB
+4.04%
INAB: Restructuring Narrows Focus to AML

By John Vandermosten, CFA NASDAQ:INAB READ THE FULL INAB RESEARCH REPORT IN8bio, Inc (NASDAQ:INAB) announced a restructuring in a September 4th press release indicating that the company will focus on the INB-100 program for acute myeloid leukemia (AML). Due to the difficult financing environment and investor lack of interest in pursuing a glioblastoma multiforme (GBM) program, IN8bio has decided

Zacks Small Cap Research 5 months ago

INAB
+4.04%
IN8bio Announces Pricing of $12.4 Million Private Placement

Cash position now expected to fund current operating plan into 2026 Financing provides cash runway to advance the ongoing expansion cohorts in the Phase 1 trial of INB-100 for patients with Acute Myeloid Leukemia (AML) NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that it has entered into a definitive securities purchase agreement with accredited inves

GlobeNewswire 5 months ago

INAB
+4.04%

Performance Overview

Return	INAB	S&P 500 (^GSPC)
YTD	-32.80%	-4.23%
1-Year	-84.98%	+7.42%
3-Year	-94.98%	+23.92%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

IN8bio, Inc. (INAB)

IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025

INAB: Introducing INB-600, A γδ T Cell Engager Platform

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference

IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

INAB: Continued Survival in INB-100 Trial

IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

IN8bio to Present at Biotech Showcase 2025 in San Francisco

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference

IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting

INAB: Upcoming Presentations at SNO & ASH

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting

IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting

INAB: Restructuring Narrows Focus to AML

IN8bio Announces Pricing of $12.4 Million Private Placement

Performance Overview